Clinical economics review: irritable bowel syndrome.

  title={Clinical economics review: irritable bowel syndrome.},
  author={Nicholas Wells and Brigitte Hahn and Peter J Whorwell},
  journal={Alimentary pharmacology & therapeutics},
  volume={11 6},
The ubiquitous nature of irritable bowel syndrome (IBS), coupled with a lack of good treatment options, has created the impression that the condition must represent a large drain on health-care resources. The literature certainly appears to support this view but is largely based on patients seen in referral centres (10-15%) and it may not be appropriate to extrapolate these data to the IBS population as a whole (85-90%). In addition to reviewing such literature that exists on the economics of… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 36 extracted citations

Quality of Life in Irritable Bowel Syndrome

PharmacoEconomics • 2001
View 14 Excerpts
Highly Influenced

A pragmatic randomised controlled trial of healing therapy in a gastroenterology outpatient setting

T. Kingstoneb, L. Robertsc, +4 authors S. Singhg
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 46 references

The epidemiology of irritable bowel syndrome in a random population: Prevalence, incidence, natural history and risk factors

L Kay, T Jorgensen, KH. Jensen
J Intern Med • 1994

Similar Papers

Loading similar papers…